C-erbB-2 Onco-protein expression in breast cancer: Relationship to tumour characterisitcs and short-term survival in Universiti Kebansaan Malaysia Medical Centre

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 4, 2008, Pages 663-670

  Sharifah, N A ^a   Lee, B R ^b   Clarence Ko, C H ^a   Tan, G C ^a   Shiran, M S ^b   Naqiyah, I ^a   Rohaizak, M ^a   Fuad, I ^a   Tamil, A M ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Breast carcinoma; C erbB 2 oncoprotein; Disease free survival; Overall survival; Prognostic factor

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; BREAST TUMOR; CANCER STAGING; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALAYSIA; METABOLISM; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; BREAST NEOPLASMS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALAYSIA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 66149115636     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. AJCC Cancer Staging Manual (5th Ed) (1997). pages 172-7.
2. Berger MS, Locher GW, Saurer S, et al (1988). Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res, 48, 1238-43.
3. Bilous M, Ades C, Armes J, et al (2003). Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast, 12, 92-8.
4. Clark GM, McGuire WL (1991). Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res, 51, 944-8.
5. Cobleigh MA, Vogel CL, Tripathy D, et al (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, 2639-48.
6. Cox DR (1972). Regression models and life tables. J R Stat Soc B, 34, 187-202.
7. Earp HS, Dawson TL, Li X, et al (1995). Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat, 35, 115-32.
8. el-Ahmady O, el-Salahy E, Mahmoud M, et al (2002). Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. Anticancer Res, 22, 2493-9.
9. Elston CW, Ellis IO. (1998). Assessment of histological grade. In 'The Breast', Eds Elston CW and Ellis IO. Churchill Livingstone, New York, pp 356-84.
10. Heintz NH, Leslie KO, Rogers LA, et al (1990). Amplification of the c-erb B-2 oncogene in prognosis of breast adenocarcinoma. Arch Pathol Lab Med, 114, 160-3.
11. Hisham AN, Yip CH (2003). Spectrum of breast cancer in Malaysian women: overview. World J Surg, 27, 921-3.
12. Jatoi I, Hilsenbeck SG, Clark GM, et al (1999). Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol, 17, 2334-40.
13. Joensuu H, Isola J, Lundin M, et al (2003). Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res, 9, 923-30.
14. Kaplan EL, Meier P (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81.
15. Lim GCC, Halimah Y (2004). Cancer Incidence in Malaysia 2003 report by Ministry of Health. National Cancer Registry Kuala Lumpur, 102-3.
16. Looi LM, Cheah PL (1998). C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Malaysian J Pathol, 20,19-23.
17. Looi LM, Cheah PL, Yap SF (1997). Correclation between histological grade and c-erbB-2 oncoprotein overexpression in infiltrating ductal carcinoma of breast. Malaysian J Pathol, 19, 35-9.
18. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-70.
19. Mori I, Yang Q, Kakudo K (2002). Predictive and prognostic markers for invasive breast cancer. Pathol International, 52, 186-94.
20. Ong TA, Yip CH (2003). Short-term survival in breast cancer: the experience of the University of Malaya Medical Centre. Asian J Surg, 26, 169-75.
21. Pauletti G, Dandekar S, Rong H, et al (2000). Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol, 18, 3651-64.
22. Penault-Llorca F, Adelaide J, Houvenaeghel G, et al (1994). Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol, 173, 65-75.
23. Perez EA, Roche PC, Jenkins RB, et al (2002). HER-2/neu testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc, 77, 148-54.
24. Ross JS, Fletcher JA, Linette GP, et al (2003). The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist, 8, 307-25.
25. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
26. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92.
27. Tesch M, Shawwa A, Henderson R (1993). Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Pathol, 99, 8-12.
28. Tsuda H, Hirohashi S, Shimosato Y, et al (1990). Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer, 65, 1794-800.
29. Yip CH, Nur Aishah MT, Ibraham M (2006). Epidemiology of breast cancer in Malaysia. Asian Pac J Cancer Prev, 7, 369-74.